Navigation Links
Echinacea No Cure for the Common Cold, Study Finds
Date:12/21/2010

By Steven Reinberg
HealthDay Reporter

MONDAY, Dec. 20 (HealthDay News) -- The herbal remedy echinacea, believed by many to cure colds, is no better than a placebo in relieving the symptoms or shortening the duration of illness, a new study finds.

"My advice is, if you are an adult and believe in echinacea, it's safe and you might get some placebo effect if nothing else," said lead researcher Dr. Bruce Barrett, an associate professor of medicine at the University of Wisconsin. "I wouldn't say the results of the trial should dissuade people who are currently using echinacea and feel that it works for them, but there is no new evidence to suggest that we have found the cure for the common cold."

If echinacea was able to significantly reduce the symptoms and length of colds, this study would have found it, Barrett noted. "With this particular dose of this particular formulation of echinacea there was no large benefit," he said.

The report is published in the Dec. 21 issue of the Annals of Internal Medicine.

In the study, Barrett's team randomly assigned 719 people with colds to no treatment, to a pill they knew was echinacea, or to a pill that could either be a placebo or echinacea, but they were not told which. The participants ranged from 12 to 80 years of age.

People in the study, which was funded by the U.S. National Center for Complementary and Alternative Medicine (part of the National Institutes of Health), reported their symptoms twice a day for about a week. Among those receiving echinacea, symptoms subsided seven to 10 hours sooner than those receiving placebo or no treatment. This represented a "small beneficial effect in persons with the common cold," according to the study. However, this slight decrease in the duration of their colds was not statistically significant, Barrett said.

There was also no statistically significant difference in the severity of symptoms between the groups, he added.

Douglas "Duffy" MacKay, vice president for scientific and regulatory affairs at the Council for Responsible Nutrition, a lobbying group for the supplement industry, said that "the cure for the common cold has been an elusive target of the medical community for decades. Unfortunately, the best available treatments for this self-limiting condition are modestly effective."

Although this study did not show that echinacea made much of a difference in fighting colds, the study was limited by its size and method of reporting results, MacKay said. "Had a larger sample size been available, it's quite possible the investigators would have observed statistically significant effects," he said.

While the study did not provide evidence that echinacea is the cure for the common cold, the evidence suggests that echinacea use should be "guided by personal health values," MacKay said.

"Consumers can also be reassured by the strong evidence of safety for echinacea," he said. The totality of evidence suggests that echinacea may shorten the duration of a cold while providing moderate symptomatic relief. This magnitude of benefit is comparable to other choices consumers have when grappling with this common and self-limiting condition."

More information

For more information on colds, visit the U.S. National Library of Medicine.

SOURCES: Bruce Barrett M.D., Ph.D., associate professor, medicine, University of Wisconsin, Madison; Douglas "Duffy" MacKay, vice president, scientific and regulatory affairs, Council for Responsible Nutrition; Dec. 21, 2010, Annals of Internal Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Adapting to clogged airways makes common pathogen resist powerful drugs
2. A common cholesterol drug fights cataracts, too
3. U.S. National Guard Connects Nationwide with Desktop Alert's Command and Control Mass Notification Systems and Common Alerting Protocol (CAP)
4. US21, Inc. is Granted a Wholesale Distributor Permit from the Commonwealth of Virginia Board of Pharmacy
5. New therapeutic target for most common solid cancer in childhood?
6. Migraine More Common in Women with MS
7. Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis
8. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
9. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
10. Common osteoporosis drugs are associated with a decrease in risk of breast cancer
11. Commonwealth Leverage Group and Helium Interactive Form HIE Go-To-Market Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Echinacea No Cure for the Common Cold, Study Finds
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform ... leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led ...
Breaking Medicine Technology: